Skip to main content
. 2022 Feb 12;11(4):e024159. doi: 10.1161/JAHA.121.024159

Figure 1. Study population by CYP2C19 group and antiplatelet therapy.

Figure 1

A total of 22/461 (5%) of patients in the LOF‐clopidogrel group were CYP2C19 PMs. A total of 76/571 (13%) of patients in the LOF‐alternative group were CYP2C19 PMs. APT indicates antiplatelet therapy; LOF, loss‐of‐functio; and PCI, percutaneous coronary intervention. *Alternative therapy in patients with 1 or 2 LOF alleles consisted of prasugrel (n=337), ticagrelor (n=219), or high‐dose clopidogrel (150 mg/day, n=4; 225 mg/day, n=11). †Alternative therapy in the non‐LOF group consisted of prasugrel (n=231), ticagrelor (n=146), or high‐dose clopidogrel (150 mg/day, n=1). #P<0.001 for use of alternative therapy in the non‐LOF group compared with the LOF group.